Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin/Topotecan vs FLAM vs S-MEC in Relapsed/Refractory AML
NCT00634244Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2008
- Primary completion
- Sep 2014
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Targeted Liposomes
- Countries
- 2
01
Overview
A Phase 2 trial of alvocidib, sirolimus, carboplatin, topotecan liposome in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Started Oct 2008; status: completed.
02
Drugs
alvocidibsirolimuscarboplatintopotecan liposome
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00634244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00634244.